Process Systems Enterprise: gPROMS FormulatedProducts 1.4 Includes Enhanced Capabilities Linking Digital Design to Digital Operations
Process Systems Enterprise (PSE), the Advanced Process Modelling company, today released version 1.4 of gPROMS FormulatedProducts, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation.
This release introduces major enhancements to both the gPROMS FormulatedProducts model libraries and the underlying gPROMS platform 6.0, including morphological crystallizer and sensor models to capture particle size and shape evolution, enhanced continuous direct compression models and improved wet granulation models. Platform enhancements include support for cluster computing, to significantly speed up execution of parameter estimation and other complex numerical solutions, and comprehensive global system analysis of dynamic systems for rapid exploration of the time-varying decision space and systematic risk and uncertainty analysis.
Version 1.4 also introduces two key usability enhancements: the ability to launch gPROMS FormulatedProducts Utilities from within the flowsheeting environment to quickly and easily configure material systems, and a user interface for rapid configuration of gPROMS FormulatedProducts models for use in Perceptive Engineering’s PharmaMV for digital operation applications.
Many of the platform and library enhancements in the new release were enabled through the financial support of and collaborative activities within the PSE-led ADDoPT project (www.addopt.org). These enhancements were showcased on 28 March at the ADDoPT Digital Design event, which included presentations from AstraZeneca, GSK, and Pfizer on the application of mechanistic models for digital design and operation of formulation and manufacturing processes.
Sean Bermingham, VP Formulated Products at PSE, said: “This release constitutes a major improvement in terms of both capability and usability for mechanistic model-based digital design and digital operation, which will enable users across the formulated product industries to design more robust products and processes, increase R&D efficiency and reduce risk in innovation and technology transfer.”
PSE continues to lead innovation in advanced process modelling capabilities for the pharmaceuticals, food & dairy, consumer products and specialty chemicals sectors. Through the support of the ADDoPT project and the Systems-based Pharmaceutics Alliance, by leveraging its experience in the energy and chemicals sectors, and via support of academic research and collaborative R&D initiatives, the company has created first-in-pharma mechanistic modelling tools, methodologies and workflows for both digital design and digital manufacturing.
For editors
‘About’: www.psenterprise.com/news/pr190418
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005026/en/
Contact information
Kristen Hunter
+44-20-8563-0888
k.hunter@psenterprise.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New CPS Protection Platform: TXOne Networks Presents SageOne in Hannover25.4.2024 09:04:00 CEST | Press release
TXOne Networks, a leading company in the field of cyber-physical systems (CPS) security, will be presenting its new CPS security platform during the Hannover Messe from 22nd to 26th April 2024 at stand B06 in hall 16: SageOne, which means Wise Man Number One. This central management console provides an overview of the CPS attack surface of the OT environment. All three TXOne product lines can be centrally controlled, namely Stellar for endpoint protection, Element for security inspection and Edge for network defense. The platform offers integrated OT security across the entire lifecycle of the objects to be protected and enables reliable detection and response to threats. SageOne essentially covers three main pillars: CPS Attack Surface Management: Visibility is a cornerstone for cybersecurity. A clear view of the overall security posture helps identify security focal points in an OT environment. SageOne focuses on operational security by honing in on assets and illuminating the securi
Infobip becomes an Oracle Independent Software Vendor partner25.4.2024 09:00:00 CEST | Press release
Infobip, a global cloud communications platform and a member of Oracle PartnerNetwork (OPN), today announced it has enhanced its relationship with Oracle, becoming an Independent Software Vendor (ISV) with access to Oracle Integration Cloud. Businesses using any Oracle solution can access Infobip’s omnichannel platform through Oracle Cloud Marketplace (OCM). They can quickly orchestrate powerful interactions, help increase customer satisfaction, boost sales, and improve campaign performance. Oracle Cloud Marketplace is a one-stop shop for Oracle customers seeking trusted business applications and services offering unique solutions, including ones that extend Oracle Fusion Cloud Applications. Infobip’s communication channels will enable businesses to deliver conversational experiences across many sectors including banking and financial services, retail and ecommerce, and hospitality and leisure. Through Infobip’s collaboration, Oracle users will gain customer insights, enabling them to
Global CIOs geared up to scale AI but organizations aren’t as ready25.4.2024 05:00:00 CEST | Press release
AI is the CIO’s top priority, according to findings of Lenovo’s third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by speed, security, and other organizational functions lagging in AI readiness. In a stark contrast to previous years, CIOs are tabling non-traditional responsibilities to sharpen their focus on core IT functions. Slightly more than half (51%) of CIOs feel AI/ML is an urgent priority to address, matched only by cybersecurity. This urgency is directly correlated to the pressure that CIOs are under to drive business impact, rather than operational maintenance and preservation. 84% of CIOs revealed they are being evaluated on business outcome metrics more than ever before. “Today’s CIOs are working in a tornado of innovation. After years of IT expanding into non-traditional responsibilities, we’re now seeing how AI is forcing CIOs back to their
Mundipharma acquires all assets and rights related to REZZAYO ® (rezafungin) , reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area24.4.2024 22:01:00 CEST | Press release
Mundipharma* today announced the acquisition of all assets and rights related to rezafungin globally from Cidara Therapeutics. This provides Mundipharma with global ownership of rezafungin including ongoing development and distribution. Rezafunginis a novel once-weekly echinocandin indicated for the treatment of invasive candidiasis in adults.1 Invasive candidiasis, is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues.2,3 It affects seriously ill people, especially those with a weakened immune systemand the mortality rate can be 40%4 or more.5,6 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays.6 Over the last 15 years, there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options.7,8 “This acquisition places Mundipharma in the best position to realise the full potential of rezafungin inclu
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting24.4.2024 22:01:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year’s ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that address the unmet needs of patients with B-cell malignancies and solid tumors,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “The exciting data we will share during ASCO showcase BRUKINSA’s uniquely differentiated clinical profile and add to the growing body of evidence supporting its role across the blood cancer treatment paradigm.” BeiGene will share new data for BRUKINSA (zanubrutinib), which add to the robust efficacy and safety evidence differentiating it within the BTK class. Key highlights include: A network meta-analysis co